Diamond Equity Forecasts MAIA Biotechnology Q1 Earnings

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) – Investment analysts at Diamond Equity issued their Q1 2025 EPS estimates for MAIA Biotechnology in a report issued on Thursday, November 14th. Diamond Equity analyst H. Diamond expects that the company will earn ($0.25) per share for the quarter. The consensus estimate for MAIA Biotechnology’s current full-year earnings is ($1.25) per share. Diamond Equity also issued estimates for MAIA Biotechnology’s Q2 2025 earnings at ($0.31) EPS, Q3 2025 earnings at ($0.36) EPS, Q4 2025 earnings at ($0.43) EPS and FY2025 earnings at ($1.35) EPS.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last issued its earnings results on Tuesday, November 12th. The company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.32) by $0.21.

MAIA Biotechnology Price Performance

Shares of NYSEAMERICAN:MAIA opened at $2.35 on Monday. MAIA Biotechnology has a 52-week low of $0.82 and a 52-week high of $5.99. The firm has a market cap of $59.53 million, a PE ratio of -1.70 and a beta of 0.32.

Institutional Investors Weigh In On MAIA Biotechnology

Several large investors have recently added to or reduced their stakes in MAIA. XTX Topco Ltd bought a new position in shares of MAIA Biotechnology during the 3rd quarter worth about $31,000. Mather Group LLC. grew its stake in MAIA Biotechnology by 50,150.0% in the second quarter. Mather Group LLC. now owns 12,060 shares of the company’s stock valued at $41,000 after acquiring an additional 12,036 shares during the period. Ground Swell Capital LLC bought a new stake in shares of MAIA Biotechnology during the second quarter valued at approximately $56,000. Virtu Financial LLC acquired a new position in shares of MAIA Biotechnology during the first quarter worth approximately $71,000. Finally, Geode Capital Management LLC lifted its holdings in shares of MAIA Biotechnology by 22.9% in the 3rd quarter. Geode Capital Management LLC now owns 192,563 shares of the company’s stock worth $541,000 after purchasing an additional 35,821 shares in the last quarter. Institutional investors and hedge funds own 5.65% of the company’s stock.

Insider Buying and Selling

In other news, Director Cristian Luput purchased 22,133 shares of the company’s stock in a transaction dated Friday, November 1st. The shares were purchased at an average price of $2.51 per share, for a total transaction of $55,553.83. Following the transaction, the director now owns 389,483 shares of the company’s stock, valued at approximately $977,602.33. This trade represents a 6.03 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 36.98% of the stock is owned by corporate insiders.

MAIA Biotechnology Company Profile

MAIA Biotechnology, Inc, a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer.